Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Biogen Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Biogen Inc. inventory turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Biogen Inc. receivables turnover ratio improved from Q1 2022 to Q2 2022 but then deteriorated significantly from Q2 2022 to Q3 2022. |
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Biogen Inc. payables turnover ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 exceeding Q1 2022 level. |
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Biogen Inc. working capital turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Biogen Inc. number of days of inventory outstanding deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | Biogen Inc. number of days of receivables outstanding improved from Q1 2022 to Q2 2022 but then deteriorated significantly from Q2 2022 to Q3 2022. |
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Biogen Inc. operating cycle deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Biogen Inc. number of days of payables outstanding increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022. |
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Biogen Inc. cash conversion cycle deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Inventory Turnover
Biogen Inc., inventory turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 469,500) | 484,000) | 753,900) | 660,100) | 511,800) | 459,700) | 478,100) | 490,700) | 449,100) | 411,100) | 454,300) | 447,100) | 430,000) | 476,300) | 602,000) | 488,500) | 460,800) | 421,000) | 446,000) | 509,200) | 370,000) | 366,200) | 384,600) | |||||||
| Inventory | 1,375,000) | 1,294,200) | 1,215,400) | 1,351,500) | 1,347,900) | 1,254,800) | 1,171,800) | 1,068,600) | 1,027,700) | 952,700) | 858,800) | 804,200) | 751,800) | 776,700) | 770,200) | 929,900) | 916,600) | 931,700) | 890,800) | 902,700) | 1,007,200) | 936,500) | 921,600) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Inventory turnover1 | 1.72 | 1.86 | 1.96 | 1.56 | 1.44 | 1.50 | 1.56 | 1.69 | 1.71 | 1.83 | 2.10 | 2.43 | 2.66 | 2.61 | 2.56 | 1.95 | 2.00 | 1.87 | 1.90 | 1.81 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.54 | 4.99 | 4.96 | 5.58 | 5.76 | 5.45 | 5.40 | 4.65 | 3.66 | 2.36 | 4.17 | 4.10 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.34 | 1.40 | 1.48 | 1.58 | 1.53 | 1.53 | 1.53 | 1.58 | 1.48 | 1.38 | 1.31 | 1.22 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 4.77 | 4.59 | 4.55 | 4.74 | 4.85 | 5.01 | 5.61 | 5.68 | 5.83 | 4.46 | 3.50 | 1.88 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 3.80 | 3.71 | 3.87 | 4.16 | 4.06 | 4.28 | 4.34 | 4.28 | 3.79 | 3.26 | 3.09 | 4.87 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.86 | 1.79 | 1.93 | 1.88 | 1.79 | 1.80 | 1.68 | 1.38 | 1.42 | 1.48 | 1.55 | 1.48 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 4.71 | 4.50 | 4.50 | 4.08 | 3.21 | 2.99 | 2.79 | 2.72 | 4.82 | 4.52 | 4.75 | 5.07 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.68 | 2.69 | 2.77 | 2.87 | 2.86 | 2.91 | 2.86 | 3.04 | 2.89 | 2.93 | 3.16 | 3.05 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 3.10 | 3.06 | 2.74 | 2.29 | 2.73 | 2.79 | 2.40 | 2.45 | 2.22 | 2.33 | 2.46 | 2.36 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.62 | 3.66 | 3.67 | 3.40 | 2.78 | 1.80 | 1.28 | 1.08 | 0.90 | 1.05 | 1.15 | 1.23 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.83 | 0.96 | 1.27 | 1.25 | 0.88 | 0.82 | 0.56 | 0.58 | 0.55 | 0.57 | 0.55 | 0.55 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 4.29 | 4.03 | 3.87 | 3.88 | 3.90 | 4.03 | 4.01 | 4.02 | 3.92 | 3.93 | 4.14 | 4.22 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 2.69 | 2.70 | 2.83 | 2.56 | 2.58 | 2.52 | 2.56 | 2.62 | 2.93 | 3.03 | 3.29 | 3.27 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Inventory turnover
= (Cost of sales, excluding amortization and impairment of acquired intangible assetsQ3 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ2 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ1 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ4 2021)
÷ Inventory
= (469,500 + 484,000 + 753,900 + 660,100)
÷ 1,375,000 = 1.72
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Biogen Inc. inventory turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Receivables Turnover
Biogen Inc., receivables turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Product, net | 1,962,100) | 2,054,900) | 2,066,300) | 2,193,500) | 2,205,700) | 2,236,000) | 2,211,700) | 2,301,600) | 2,690,300) | 2,795,700) | 2,904,600) | 2,924,800) | 2,894,700) | 2,880,300) | 2,680,000) | 2,825,700) | 2,780,100) | 2,757,500) | 2,523,500) | 2,712,400) | 2,622,500) | 2,639,700) | 2,380,100) | |||||||
| Accounts receivable, net | 1,568,800) | 1,567,600) | 1,632,000) | 1,549,400) | 1,723,000) | 1,688,000) | 1,854,300) | 1,913,800) | 2,024,900) | 2,133,600) | 2,092,600) | 1,880,500) | 1,933,500) | 1,959,600) | 2,088,900) | 1,958,500) | 2,017,300) | 1,951,000) | 1,939,200) | 1,787,000) | 1,567,500) | 1,630,200) | 1,501,500) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Receivables turnover1 | 5.28 | 5.44 | 5.33 | 5.71 | 5.20 | 5.59 | 5.39 | 5.59 | 5.59 | 5.40 | 5.55 | 6.05 | 5.83 | 5.70 | 5.29 | 5.56 | 5.34 | 5.44 | 5.41 | 5.79 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 5.38 | 5.10 | 5.29 | 5.63 | 5.94 | 5.42 | 5.24 | 5.19 | 4.83 | 4.34 | 5.35 | 6.13 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 4.60 | 4.62 | 4.81 | 4.96 | 5.11 | 5.39 | 5.41 | 5.36 | 5.81 | 4.31 | 4.55 | 5.47 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 7.09 | 6.81 | 6.87 | 6.36 | 6.69 | 6.51 | 6.28 | 5.51 | 5.83 | 5.59 | 5.25 | 5.61 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.35 | 4.57 | 4.64 | 4.24 | 4.69 | 4.58 | 4.56 | 4.18 | 4.75 | 4.75 | 4.52 | 4.91 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 6.16 | 6.60 | 7.18 | 6.01 | 5.95 | 6.34 | 6.43 | 4.98 | 5.83 | 6.84 | 5.73 | 6.18 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 6.04 | 5.92 | 6.08 | 6.14 | 6.13 | 6.00 | 5.64 | 6.08 | 5.55 | 5.50 | 5.56 | 5.67 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 6.22 | 5.93 | 5.49 | 5.28 | 5.56 | 6.00 | 5.65 | 6.11 | 5.62 | 6.23 | 5.88 | 6.91 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 6.21 | 6.68 | 6.99 | 7.08 | 5.81 | 5.23 | 4.70 | 5.28 | 4.29 | 4.96 | 4.93 | 5.93 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.47 | 2.76 | 3.41 | 2.66 | 2.48 | 1.77 | 2.20 | 2.07 | 2.04 | 2.84 | 2.72 | 2.94 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.76 | 5.53 | 5.21 | 4.92 | 7.03 | 6.99 | 6.46 | 5.61 | 5.49 | 5.86 | 5.69 | 5.87 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 6.28 | 6.26 | 6.15 | 6.66 | 6.48 | 7.19 | 6.56 | 7.01 | 7.57 | 6.82 | 5.70 | 6.57 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Receivables turnover
= (Product, netQ3 2022
+ Product, netQ2 2022
+ Product, netQ1 2022
+ Product, netQ4 2021)
÷ Accounts receivable, net
= (1,962,100 + 2,054,900 + 2,066,300 + 2,193,500)
÷ 1,568,800 = 5.28
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Biogen Inc. receivables turnover ratio improved from Q1 2022 to Q2 2022 but then deteriorated significantly from Q2 2022 to Q3 2022. |
Payables Turnover
Biogen Inc., payables turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 469,500) | 484,000) | 753,900) | 660,100) | 511,800) | 459,700) | 478,100) | 490,700) | 449,100) | 411,100) | 454,300) | 447,100) | 430,000) | 476,300) | 602,000) | 488,500) | 460,800) | 421,000) | 446,000) | 509,200) | 370,000) | 366,200) | 384,600) | |||||||
| Accounts payable | 383,200) | 434,800) | 398,700) | 589,200) | 427,900) | 375,300) | 430,400) | 454,900) | 398,400) | 383,900) | 389,000) | 530,800) | 382,200) | 377,100) | 378,000) | 370,500) | 342,300) | 295,700) | 345,800) | 395,500) | 298,700) | 330,300) | 316,400) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Payables turnover1 | 6.18 | 5.54 | 5.98 | 3.58 | 4.53 | 5.00 | 4.25 | 3.97 | 4.42 | 4.54 | 4.65 | 3.68 | 5.22 | 5.38 | 5.22 | 4.90 | 5.37 | 5.91 | 4.89 | 4.12 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 5.30 | 5.09 | 4.65 | 4.72 | 5.41 | 4.92 | 4.40 | 4.33 | 5.01 | 4.60 | 3.60 | 3.18 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.82 | 3.41 | 3.25 | 3.37 | 3.89 | 2.97 | 3.69 | 4.34 | 4.65 | 3.73 | 3.23 | 3.30 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 5.61 | 5.00 | 5.04 | 4.48 | 5.20 | 5.54 | 5.29 | 4.79 | 5.46 | 5.28 | 4.55 | 5.23 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.24 | 4.21 | 5.24 | 4.38 | 4.46 | 4.30 | 3.75 | 3.41 | 3.53 | 3.92 | 3.97 | 3.36 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 11.22 | 11.89 | 11.43 | 9.36 | 9.18 | 8.70 | 8.71 | 5.42 | 9.22 | 8.93 | 7.94 | 6.56 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 3.08 | 3.15 | 3.26 | 2.70 | 3.32 | 3.38 | 3.34 | 2.99 | 3.94 | 4.09 | 3.78 | 3.23 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 5.16 | 4.86 | 4.25 | 2.96 | 4.54 | 3.93 | 3.81 | 3.37 | 3.64 | 4.10 | 4.02 | 3.78 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 5.49 | 6.17 | 6.66 | 5.53 | 5.11 | 3.72 | 2.68 | 2.02 | 2.02 | 2.32 | 2.45 | 2.42 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.74 | 4.00 | 5.39 | 4.32 | 4.23 | 3.42 | 2.23 | 2.36 | 2.24 | 2.48 | 2.36 | 1.87 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 9.93 | 8.84 | 7.96 | 6.83 | 8.31 | 8.88 | 8.12 | 7.45 | 8.82 | 10.35 | 8.93 | 7.40 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 8.23 | 5.01 | 5.52 | 4.64 | 6.73 | 6.35 | 5.99 | 4.75 | 6.66 | 6.54 | 6.11 | 6.25 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Payables turnover
= (Cost of sales, excluding amortization and impairment of acquired intangible assetsQ3 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ2 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ1 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ4 2021)
÷ Accounts payable
= (469,500 + 484,000 + 753,900 + 660,100)
÷ 383,200 = 6.18
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Biogen Inc. payables turnover ratio decreased from Q1 2022 to Q2 2022 but then increased from Q2 2022 to Q3 2022 exceeding Q1 2022 level. |
Working Capital Turnover
Biogen Inc., working capital turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current assets | 9,765,800) | 9,740,900) | 7,915,900) | 7,856,500) | 7,162,300) | 7,183,700) | 6,719,500) | 6,887,100) | 7,843,100) | 8,493,800) | 8,007,200) | 8,381,800) | 8,448,200) | 7,909,800) | 8,942,600) | 7,640,900) | 8,719,000) | 7,432,100) | 10,195,400) | 7,873,300) | 7,568,000) | 7,108,700) | 6,859,700) | |||||||
| Less: Current liabilities | 3,926,400) | 5,018,000) | 3,946,600) | 4,298,200) | 4,211,600) | 3,347,200) | 3,165,800) | 3,742,200) | 3,804,000) | 3,447,100) | 4,638,600) | 4,863,800) | 4,432,200) | 3,210,900) | 3,148,700) | 3,295,200) | 3,174,900) | 3,152,400) | 3,152,100) | 3,368,200) | 3,448,400) | 3,379,700) | 2,992,500) | |||||||
| Working capital | 5,839,400) | 4,722,900) | 3,969,300) | 3,558,300) | 2,950,700) | 3,836,500) | 3,553,700) | 3,144,900) | 4,039,100) | 5,046,700) | 3,368,600) | 3,518,000) | 4,016,000) | 4,698,900) | 5,793,900) | 4,345,700) | 5,544,100) | 4,279,700) | 7,043,300) | 4,505,100) | 4,119,600) | 3,729,000) | 3,867,200) | |||||||
| Product, net | 1,962,100) | 2,054,900) | 2,066,300) | 2,193,500) | 2,205,700) | 2,236,000) | 2,211,700) | 2,301,600) | 2,690,300) | 2,795,700) | 2,904,600) | 2,924,800) | 2,894,700) | 2,880,300) | 2,680,000) | 2,825,700) | 2,780,100) | 2,757,500) | 2,523,500) | 2,712,400) | 2,622,500) | 2,639,700) | 2,380,100) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Working capital turnover1 | 1.42 | 1.80 | 2.19 | 2.49 | 3.03 | 2.46 | 2.81 | 3.40 | 2.80 | 2.28 | 3.44 | 3.23 | 2.81 | 2.38 | 1.91 | 2.51 | 1.94 | 2.48 | 1.49 | 2.30 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | 130.12 | — | — | — | — | — | 0.97 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.52 | 3.67 | 4.34 | 3.37 | 2.55 | 5.35 | 2.84 | 2.55 | 1.87 | 1.87 | 3.27 | 3.96 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 5.75 | 4.92 | 6.24 | 3.95 | 4.43 | 4.24 | 4.25 | 3.72 | 2.77 | 3.09 | 2.38 | 2.28 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 5.00 | 5.43 | 5.91 | 8.40 | 7.98 | 3.12 | 3.45 | 3.48 | 3.14 | 2.80 | 6.74 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 14.71 | 19.45 | 8.19 | 8.33 | 6.73 | 12.14 | 5.21 | 4.93 | 5.45 | 8.85 | 16.68 | 11.54 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 8.56 | 6.87 | 6.68 | 8.54 | 7.25 | 7.09 | 7.06 | 5.30 | 1.07 | 1.55 | 1.24 | 1.08 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 4.88 | 5.02 | 5.57 | 5.95 | 5.97 | 5.93 | 7.26 | 9.44 | 4.32 | 8.83 | 7.85 | 8.81 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 5.58 | 6.39 | 6.09 | 7.62 | 6.51 | 6.97 | 84.97 | 109.83 | 7.67 | 6.59 | 17.87 | 8.90 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.83 | 5.05 | 6.10 | 4.78 | 4.29 | 4.21 | 3.60 | 4.58 | 3.16 | 3.31 | 57.45 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.09 | 1.14 | 1.46 | 1.59 | 1.35 | 1.29 | 1.35 | 1.20 | 1.22 | 1.92 | 1.21 | 1.41 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.40 | 6.03 | 6.13 | 5.87 | 2.30 | 3.10 | 3.36 | 2.76 | 2.37 | 2.69 | 3.54 | 4.48 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 0.90 | 0.93 | 0.97 | 1.02 | 1.03 | 1.01 | 0.97 | 0.99 | 1.10 | 1.10 | 1.23 | 1.19 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Working capital turnover
= (Product, netQ3 2022
+ Product, netQ2 2022
+ Product, netQ1 2022
+ Product, netQ4 2021)
÷ Working capital
= (1,962,100 + 2,054,900 + 2,066,300 + 2,193,500)
÷ 5,839,400 = 1.42
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Biogen Inc. working capital turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Average Inventory Processing Period
Biogen Inc., average inventory processing period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Inventory turnover | 1.72 | 1.86 | 1.96 | 1.56 | 1.44 | 1.50 | 1.56 | 1.69 | 1.71 | 1.83 | 2.10 | 2.43 | 2.66 | 2.61 | 2.56 | 1.95 | 2.00 | 1.87 | 1.90 | 1.81 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average inventory processing period1 | 212 | 196 | 186 | 234 | 254 | 244 | 234 | 216 | 213 | 200 | 173 | 150 | 137 | 140 | 143 | 187 | 182 | 195 | 192 | 202 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 66 | 73 | 74 | 65 | 63 | 67 | 68 | 79 | 100 | 155 | 88 | 89 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 272 | 260 | 247 | 231 | 239 | 239 | 239 | 231 | 247 | 265 | 279 | 300 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 76 | 79 | 80 | 77 | 75 | 73 | 65 | 64 | 63 | 82 | 104 | 194 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 96 | 98 | 94 | 88 | 90 | 85 | 84 | 85 | 96 | 112 | 118 | 75 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 196 | 204 | 189 | 194 | 204 | 203 | 217 | 265 | 257 | 247 | 236 | 247 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 78 | 81 | 81 | 89 | 114 | 122 | 131 | 134 | 76 | 81 | 77 | 72 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 136 | 136 | 132 | 127 | 128 | 125 | 128 | 120 | 126 | 124 | 116 | 119 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 118 | 119 | 133 | 159 | 134 | 131 | 152 | 149 | 164 | 156 | 148 | 155 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 101 | 100 | 99 | 107 | 131 | 203 | 284 | 338 | 405 | 348 | 316 | 296 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 440 | 379 | 287 | 292 | 415 | 445 | 653 | 625 | 664 | 635 | 659 | 661 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 85 | 91 | 94 | 94 | 94 | 91 | 91 | 91 | 93 | 93 | 88 | 87 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 136 | 135 | 129 | 143 | 142 | 145 | 142 | 139 | 125 | 121 | 111 | 112 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.72 = 212
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Biogen Inc. number of days of inventory outstanding deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Average Receivable Collection Period
Biogen Inc., average receivable collection period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Receivables turnover | 5.28 | 5.44 | 5.33 | 5.71 | 5.20 | 5.59 | 5.39 | 5.59 | 5.59 | 5.40 | 5.55 | 6.05 | 5.83 | 5.70 | 5.29 | 5.56 | 5.34 | 5.44 | 5.41 | 5.79 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average receivable collection period1 | 69 | 67 | 68 | 64 | 70 | 65 | 68 | 65 | 65 | 68 | 66 | 60 | 63 | 64 | 69 | 66 | 68 | 67 | 67 | 63 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 68 | 72 | 69 | 65 | 61 | 67 | 70 | 70 | 76 | 84 | 68 | 60 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 79 | 79 | 76 | 74 | 71 | 68 | 67 | 68 | 63 | 85 | 80 | 67 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 51 | 54 | 53 | 57 | 55 | 56 | 58 | 66 | 63 | 65 | 69 | 65 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 84 | 80 | 79 | 86 | 78 | 80 | 80 | 87 | 77 | 77 | 81 | 74 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 59 | 55 | 51 | 61 | 61 | 58 | 57 | 73 | 63 | 53 | 64 | 59 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 60 | 62 | 60 | 59 | 60 | 61 | 65 | 60 | 66 | 66 | 66 | 64 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 59 | 62 | 66 | 69 | 66 | 61 | 65 | 60 | 65 | 59 | 62 | 53 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 59 | 55 | 52 | 52 | 63 | 70 | 78 | 69 | 85 | 74 | 74 | 62 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 148 | 132 | 107 | 137 | 147 | 206 | 166 | 177 | 179 | 128 | 134 | 124 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 63 | 66 | 70 | 74 | 52 | 52 | 56 | 65 | 66 | 62 | 64 | 62 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 58 | 58 | 59 | 55 | 56 | 51 | 56 | 52 | 48 | 53 | 64 | 56 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.28 = 69
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | Biogen Inc. number of days of receivables outstanding improved from Q1 2022 to Q2 2022 but then deteriorated significantly from Q2 2022 to Q3 2022. |
Operating Cycle
Biogen Inc., operating cycle calculation (quarterly data)
No. days
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | 212 | 196 | 186 | 234 | 254 | 244 | 234 | 216 | 213 | 200 | 173 | 150 | 137 | 140 | 143 | 187 | 182 | 195 | 192 | 202 | — | — | — | |||||||
| Average receivable collection period | 69 | 67 | 68 | 64 | 70 | 65 | 68 | 65 | 65 | 68 | 66 | 60 | 63 | 64 | 69 | 66 | 68 | 67 | 67 | 63 | — | — | — | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Operating cycle1 | 281 | 263 | 254 | 298 | 324 | 309 | 302 | 281 | 278 | 268 | 239 | 210 | 200 | 204 | 212 | 253 | 250 | 262 | 259 | 265 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 134 | 145 | 143 | 130 | 124 | 134 | 138 | 149 | 176 | 239 | 156 | 149 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 351 | 339 | 323 | 305 | 310 | 307 | 306 | 299 | 310 | 350 | 359 | 367 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 147 | 152 | 147 | 145 | 145 | 141 | 142 | 151 | 159 | 177 | 187 | 140 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 280 | 284 | 268 | 280 | 282 | 283 | 297 | 352 | 334 | 324 | 317 | 321 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 137 | 136 | 132 | 150 | 175 | 180 | 188 | 207 | 139 | 134 | 141 | 131 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 196 | 198 | 192 | 186 | 188 | 186 | 193 | 180 | 192 | 190 | 182 | 183 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 177 | 181 | 199 | 228 | 200 | 192 | 217 | 209 | 229 | 215 | 210 | 208 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 160 | 155 | 151 | 159 | 194 | 273 | 362 | 407 | 490 | 422 | 390 | 358 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 588 | 511 | 394 | 429 | 562 | 651 | 819 | 802 | 843 | 763 | 793 | 785 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 148 | 157 | 164 | 168 | 146 | 143 | 147 | 156 | 159 | 155 | 152 | 149 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 194 | 193 | 188 | 198 | 198 | 196 | 198 | 191 | 173 | 174 | 175 | 168 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 212 + 69 = 281
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Biogen Inc. operating cycle deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Average Payables Payment Period
Biogen Inc., average payables payment period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Payables turnover | 6.18 | 5.54 | 5.98 | 3.58 | 4.53 | 5.00 | 4.25 | 3.97 | 4.42 | 4.54 | 4.65 | 3.68 | 5.22 | 5.38 | 5.22 | 4.90 | 5.37 | 5.91 | 4.89 | 4.12 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average payables payment period1 | 59 | 66 | 61 | 102 | 80 | 73 | 86 | 92 | 83 | 80 | 79 | 99 | 70 | 68 | 70 | 74 | 68 | 62 | 75 | 89 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 69 | 72 | 78 | 77 | 67 | 74 | 83 | 84 | 73 | 79 | 101 | 115 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 96 | 107 | 112 | 108 | 94 | 123 | 99 | 84 | 78 | 98 | 113 | 110 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 65 | 73 | 72 | 82 | 70 | 66 | 69 | 76 | 67 | 69 | 80 | 70 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 86 | 87 | 70 | 83 | 82 | 85 | 97 | 107 | 103 | 93 | 92 | 109 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 33 | 31 | 32 | 39 | 40 | 42 | 42 | 67 | 40 | 41 | 46 | 56 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 118 | 116 | 112 | 135 | 110 | 108 | 109 | 122 | 93 | 89 | 97 | 113 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 71 | 75 | 86 | 123 | 80 | 93 | 96 | 108 | 100 | 89 | 91 | 97 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 66 | 59 | 55 | 66 | 71 | 98 | 136 | 181 | 180 | 157 | 149 | 151 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 98 | 91 | 68 | 84 | 86 | 107 | 164 | 155 | 163 | 147 | 155 | 195 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 37 | 41 | 46 | 53 | 44 | 41 | 45 | 49 | 41 | 35 | 41 | 49 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 44 | 73 | 66 | 79 | 54 | 57 | 61 | 77 | 55 | 56 | 60 | 58 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.18 = 59
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Biogen Inc. number of days of payables outstanding increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022. |
Cash Conversion Cycle
Biogen Inc., cash conversion cycle calculation (quarterly data)
No. days
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | 212 | 196 | 186 | 234 | 254 | 244 | 234 | 216 | 213 | 200 | 173 | 150 | 137 | 140 | 143 | 187 | 182 | 195 | 192 | 202 | — | — | — | |||||||
| Average receivable collection period | 69 | 67 | 68 | 64 | 70 | 65 | 68 | 65 | 65 | 68 | 66 | 60 | 63 | 64 | 69 | 66 | 68 | 67 | 67 | 63 | — | — | — | |||||||
| Average payables payment period | 59 | 66 | 61 | 102 | 80 | 73 | 86 | 92 | 83 | 80 | 79 | 99 | 70 | 68 | 70 | 74 | 68 | 62 | 75 | 89 | — | — | — | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Cash conversion cycle1 | 222 | 197 | 193 | 196 | 244 | 236 | 216 | 189 | 195 | 188 | 160 | 111 | 130 | 136 | 142 | 179 | 182 | 200 | 184 | 176 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | 282 | 267 | 245 | 228 | 243 | 233 | 223 | 215 | 237 | 271 | 258 | 252 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 82 | 79 | 75 | 63 | 75 | 75 | 73 | 75 | 92 | 108 | 107 | 70 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 194 | 197 | 198 | 197 | 200 | 198 | 200 | 245 | 231 | 231 | 225 | 212 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 104 | 105 | 100 | 111 | 135 | 138 | 146 | 140 | 99 | 93 | 95 | 75 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 78 | 82 | 80 | 51 | 78 | 78 | 84 | 58 | 99 | 101 | 85 | 70 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 106 | 106 | 113 | 105 | 120 | 99 | 121 | 101 | 129 | 126 | 119 | 111 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 94 | 96 | 96 | 93 | 123 | 175 | 226 | 226 | 310 | 265 | 241 | 207 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 490 | 420 | 326 | 345 | 476 | 544 | 655 | 647 | 680 | 616 | 638 | 590 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 111 | 116 | 118 | 115 | 102 | 102 | 102 | 107 | 118 | 120 | 111 | 100 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 150 | 120 | 122 | 119 | 144 | 139 | 137 | 114 | 118 | 118 | 115 | 110 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 212 + 69 – 59 = 222
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Biogen Inc. cash conversion cycle deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |